ESTRO 2025 - Abstract Book

S551

Clinical - Breast

ESTRO 2025

and eight years LC for patients TN were 93.2% and 90.5% compared to 99.3% and 98.9% for patients who were not TN . Regional control (RC) at 5 and 8 years were 98.2% and 97.8%. . Local-regional control (LRC) at 5 and 8 years were97.9% and 97%. Disease-free survival (DFS) at 5 and 8 years were 96.1% and 94.3%. At univariate analysis, LC was associated with LVI and TN status with a p-value of <0.01 and 0.02 respectively. DFS with LVI and TN (p-value: 0.03 and <0.01) (Table1).

At MVA in the LC and DFS , LVI and TN status are confirmed as a negative prognostic factors with a p-value of 0.01 and 0.03 (Table2).

Conclusion: We confirmed the prognostic factors of TN status and LVI in terms of local control. PMRT for T1-2 and 1-3 positive axillary lymph nodes could be reconsidered according to the prognostic factors and the decision must be individually.

Keywords: early-stage breast cancer, PMRT